Alger, Emily
Van Zyl, Mary
Aiyegbusi, Olalekan Lee
Chuter, Dave
Dean, Lizzie
Minchom, Anna
Yap, Christina
Funding for this research was provided by:
MRC/NIHR Trials Methodology Research Partnership
Article History
Received: 12 March 2024
Accepted: 13 June 2024
First Online: 19 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd, Merck, GSK, Anthony Nolan, and Sarcoma UK. He declares personal fees from Gilead Sciences, Merck, and GlaxoSmithKline outside the submitted work.AM is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust. She has served on advisory boards for Janssen Pharmaceuticals, Merck Pharmaceuticals, Takeda Pharmaceuticals, MSD Pharmaceuticals and Genmab Pharmaceuticals. Has received honoraria from Chugai Pharmaceuticals, Novartis Oncology, Faron Pharmaceuticals, Bayer Pharmaceuticals, Merck Pharmaceuticals, GSK, Seagen Pharmaceuticals and Janssen Pharmaceuticals. Has received expenses from Amgen Pharmaceuticals and LOXO Oncology. Has received research funding from Merck Pharmaceuticals and MSD.